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ABSTRACT : Objective: To explore how much of the coronary heart disease (CHD) mor-
tality fall in England and Wales can be attributed to changes in smoking prevalence. Meth-
ods: A previously validated cell-based IMPACT CHD mortality model was used to estimate 
the deaths prevented or postponed by changes in population smoking prevalence in England 
and Wales between 1981 and 2000. CHD mortality statistics and population trends in smok-
ing were obtained from routine data sources. Results: In England and Wales between 1981 
and 2000, smoking prevalence in adults aged 25-84 decreased from 43% to 28% in men and 
from 35% to 24% in women. In men, most of the decrease occurred in those aged over 55. 
Smoking prevalence changed little in older women. An estimated 29,460 deaths were pre-
vented or postponed (DPP) by this population reduction in smoking prevalence. Most of this 
benefit was seen in men (86% of the DPPs versus 14% in women). Conclusion: Large de-
clines in smoking prevalence accounted for 29,460 fewer CHD deaths in England and Wales 
in 2000 compared with 1981. This emphasises the importance of a national strategy with 
comprehensive tobacco control programmes to further reduce smoking.  
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INTRODUCTION 
 
Coronary heart disease (CHD) caused over 
125,000 deaths in the UK in 2000. CHD mortality rates 
have been falling in most industrial countries since the 
1970s[1]. Many authors attribute more of the CHD 
mortality fall to reductions in major risk factors such as 
smoking, cholesterol and blood pressure [2-4] rather 
than cardiological treatments [5,6]. It is suggested that 
between 20% [7] and 40% [8] of CHD deaths in men 
and women can be attributed to smoking in the UK.  
Smokers demonstrate a two- to three-fold in-
crease in the incidence of CHD compared with non-
smokers[9], in men and women [10]. Smoking appears 
to increase CHD risk primarily through thrombosis 
(blood clotting). Some authors argue that smoking acts 
almost exclusively through thrombosis [11], while oth-
ers suggest that smoking also promotes atherosclerosis 
[12]. If the main effect of smoking is thrombogenic 
rather than atherosclerotic, it would be plausible to ex-
pect that risk decline could occur rapidly on smoking 
cessation. The 1990 US Surgeon General’s Report 
states that the risk is halved within 1-2 years and risk 
returns to that of a non-smoker after 15 years of absti-
nence [13].  
Treating illness and disease caused by smoking is 
estimated to cost the NHS up to £1.7 billion every year 
in terms of general practitioner visits, prescriptions, 
treatment and operations [14]. To tackle the smoking 
problem and reduce smoking prevalence in the UK, the 
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government published The White Paper on Tobacco in 
1998 [15]. In this document, targets were set to reduce 
smoking among children from 13% to 9% or less, and 
among adults from 28% to 24% or less by 2010.  
We therefore explored how much of the substan-
tial CHD mortality fall in England and Wales between 
1981-2000 could be attributed to reduction in smoking 
prevalence in the population. 
 
METHODS 
 
The cell-based IMPACT mortality model, previ-
ously validated in Scotland [16] and New Zealand [17], 
was further developed and refined to combine data for 
men and women, aged 25 to 84 in England and Wales 
describing: a) CHD patient numbers, b) uptake of spe-
cific medical and surgical treatments c) population 
trends in major cardiovascular risk factors (smoking, 
cholesterol, hypertension, obesity, diabetes, physical 
activity and deprivation) and d) effectiveness of spe-
cific cardiological treatments and risk factor reductions.  
 
Identification and assessment of relevant data 
Population and patient information: Information 
on population, demographic changes, mortality and 
acute myocardial infarction incidence was based princi-
pally on routine health statistics from the Office for 
National Statistics [18,19] and the British Heart Foun-
dation’s Annual CHD Statistics [7].  
Population risk factor trend data: Changes in the 
prevalence of measurable risk factors, including smok-
ing, cholesterol, diabetes and blood pressure, were prin-
cipally obtained from The British Regional Heart 
Study[20], the General Household Survey (GHS) [21], 
and the Health Survey for England [22]. Good data on 
smoking prevalence trends were easily available from 
successive General Household Surveys since 1974 
[21,23]. The GHS is a continuous multipurpose survey 
of people living in private households, conducted by the 
Social Survey Division of the Office for National Sta-
tistics. A representative sample of all households is 
drawn from the postal address file. These households 
are then visited and data are collected on a wide range 
of matters for all residents aged 16 and over. In even-
numbered years individuals are asked questions on 
smoking. 
 
The IMPACT Model 
The current IMPACT Model aimed to include all 
medical and surgical treatments given in 1981 and 
2000. The interventions considered in this study were 
those used in earlier versions of the IMPACT Model 
[16,17], along with primary angioplasty for myocardial 
infarction, statins in primary prevention, PG IIB/IIIA 
inhibitors for unstable angina, and spironolactone and 
beta blockers for heart failure (Appendix 1). Obesity, 
diabetes, physical activity and deprivation were the new 
cardiovascular risk factors included in the model. 
The Microsoft Excel cell-based CHD mortality 
model has been described in detail elsewhere [16,17]. 
In brief, the number of CHD deaths expected in 2000 if 
mortality rates had not fallen since 1981 was calculated 
by indirect age standardisation using 1981 as a base 
year. 
 
Calculation of treatment effectiveness 
The number of CHD deaths prevented or post-
poned in England and Wales in 1981, and again in 
2000, were calculated for specific interventions, such as 
thrombolysis, coronary artery bypass grafting, aspirin 
and so on. Each specific mortality reduction was de-
rived from the relative mortality reductions reported in 
published randomised controlled trials and meta-
analyses. Survival benefit over a minimum time interval 
of one year was calculated for all treatments and all 
patient groups both in hospital and in the commu-
nity[16] as in the example below: 
Men aged 55-64 given aspirin for acute myocar-
dial infarction: In the Antithrombotic Trialists' Col-
laboration meta-analysis, aspirin reduced relative mor-
tality in men with acute myocardial infarction by 15% 
[24]. In England and Wales in 2000, 10,699 men aged 
55-64 were eligible for aspirin treatment for acute myo-
cardial infarction, and 95% received aspirin [25]. One 
year case fatality in men aged 55-64 admitted with 
an acute myocardial infarction was approximately 
17% [26]. 
The deaths prevented or postponed for at least a 
year were therefore calculated as: Patient numbers x 
treatment uptake x relative mortality reduction x one-
year case fatality = 10,699 x 95% x 15% x 17% = 259 
deaths prevented or postponed. 
Some uncertainty obviously surrounded each of 
the estimates. Therefore a sensitivity analysis was per-
formed using analysis of extremes method [27] where-
by the maximum and minimum feasible values were fed 
into the model. For therapeutic effectiveness, 95% con-
fidence intervals for relative risks from meta-analyses 
were used as maximum and minimum estimates. Patient 
numbers were assumed to be reasonably accurate (no 
more than 10% higher or lower than our “best” esti-
mates), but treatment uptake was more uncertain (values  
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Table 1. Change in CHD deaths, smoking prevalence in men and women, England and Wales, 1981-2000 
CHD Mortality 
Rates  
(per 10000) 
Smoking Prevalence 
(%) 
Deaths Prevented / Postponed
Sex and Age 
Groups 
1981  2000 
 
Relative 
Change
%  1981  2000 
 
Relative 
Change
%      Number (min-max) 
Men              
 25-34  6.5  2.4  - 63  47 39  - 17  24 
 35-44  50.8  18.7  - 63  46 31  - 33  302 
 45-54  249.4  89.3  - 64  46 28  - 39  1,632 
 55-64  680.6  282.4  - 59  43 24  - 44  4,840 
 65-74  1562.1  807.2  - 48  35 16  - 54  10,303 
 75-84  2926.8  1896.9  - 35  34 11  - 68  8,187 
Total  556.0  213.8  - 62  43  28  - 36      25,289 (11,523-35,469) 
Women            
 25-34  1.3 0.6 - 54  43 32  - 26  6 
 35-44  8.5 4.5 - 47  41 28  - 32  40 
 45-54  47.4 18.7 - 61  42 25  - 40  260 
 55-64  196.4 78.4  - 59  39 23  - 41  912 
 65-74  659.1 335.2  - 49  24 18  - 25  1,727 
 75-84  1726.7 1053.3  - 39  11 10  - 9  1,227 
Total  315.6  173.3  - 45  35  24  - 27  4,172 (2,365- 7,760) 
 TOTAL  432  193.2  - 55  39  26  - 34  29,461 (13,888-43,229) 
 
50% higher or lower). By multiplying through, the re-
sulting product then generated maximum and minimum 
estimates for deaths prevented or postponed. 
Efficacy data: Data on efficacy of interventions 
and risk factor changes were obtained from published 
randomised controlled trials, meta-analyses and popula-
tion studies. Each β coefficient (quantifying the fall in 
CHD mortality rate attributable to the change in a spe-
cific risk factor prevalence) in the existing IMPACT 
Model was reviewed and updated to include the latest 
pooled  β coefficients published from MONICA and 
elsewhere[1].  
There were a range of different coefficients or 
relative risks describing the relationship between the 
risk factors and coronary heart disease mortality (Ap-
pendix 2). Regression (β) coefficients identified for 
smoking ranged between 0.4 [28] and 0.73 [1] implying 
a 0.4%-0.73% fall in CHD mortality for every 1% fall 
in smoking. The best estimate for smoking 0.51 was 
taken from the MONICA study in Iceland [4]. The β 
coefficients for smoking, cholesterol and blood pressure 
were reduced among groups aged >65 years to reflect 
good epidemiological evidence suggesting that relative 
risk is attenuated by age [29,30].  
Risk factor trends and mortality benefits 
The CHD mortality reduction attributable to de-
clines in specific risk factors was principally based on a 
regression method. This used the mean β coefficients 
for smoking, cholesterol and blood pressure derived 
from eight pooled MONICA cohort studies in Finland, 
Iceland and Australasia [2-4,28].  
The deaths prevented or postponed between 1981 
and 2000 were calculated as: CHD deaths in that age 
group in 1981 x risk factor decline x β coefficient. 
In England and Wales, in men aged 55-64 there 
were 18,255 CHD deaths in 1981; smoking prevalence 
fell from 43% to 24% between 1981-2000, an absolute 
reduction of 19%, and a relative reduction of 44%. Best 
estimate of β coefficient for smoking was 0.51.  
Thus, 18,255 x 44% x 0.51 = 4,096 deaths were 
prevented or postponed due to a fall in smoking preva-
lence in men aged 55-64 between 1981 and 2000. 
This calculation was then repeated a) for men and 
women in each age group, b) for each risk factor, and c) 
for maximum and minimum values in each group. 
 
Validation of IMPACT Model 
The model estimate for the total deaths prevented 
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or postponed by all treatments plus all risk factor 
changes was then compared with the observed falls in 
mortality for men and women in specific age groups. 
There was generally good agreement between estimated 
and observed falls for men and women in each age 
group. Overall, the model explained 91% of the CHD 
mortality fall. 
 
RESULTS  
 
Between 1981 and 2000, CHD mortality rates fell 
by 55% in England and Wales, with 68,230 fewer CHD 
deaths than expected in men and women aged 25 to 84.  
Some 42% of this fall was attributed to treatments 
in individuals and 58% to population risk factor 
changes [31]. Coronary heart disease treatments pro-
duced a best estimate of 25,955 fewer deaths (minimum 
estimate 13,390, maximum 39,295). Declines in the 
major cardiovascular risk factors together produced a 
best estimate of 36,110 fewer deaths (minimum esti-
mate 18,950, maximum 43,820).  
The majority of this fall was attributable to reduc-
tions in population smoking prevalence (43%), choles-
terol (13%), and blood pressure (10%) [31]. 
Smoking prevalence decreased from 43% to 28% 
in men and from 35% to 24% in women between 1981-
2000. In men, most of the decrease was in those aged 
over 55. Smoking prevalence changed little in older 
women (Table 1). There were an estimated 29,460 
(13,885-43,230) DPP by this population reduction in 
smoking prevalence. Most of this impact was in men 
(86% of the DPPs were in men and 14% in women) 
(Figure 1).  
 
DISCUSSION 
 
Between 1981 and 2000 CHD mortality halved 
and smoking prevalence decreased by a third. 
This decline in smoking prevalence explained ap-
proximately 43% of the total CHD mortality fall. Sub-
stantial declines in smoking prevalence were seen in 
men, and also women between 1981 and 2000. The 
underlying reasons are complex and may reflect both 
social and physiological factors [32]. Smoking peaked 
in the 1950s and 1960s, and fell steadily in the 1970s 
[33]. In England and Wales this decline in smoking 
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Figure 1. Percentage change in smoking prevalence and % distribution of deaths prevented or postponed (DPP) 
attributed to smoking decline by sex and age group. 
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prevalence over more than two decades principally re-
flects a smoking cessation effect rather than a cohort 
effect. However, the fall in smoking prevalence appears 
to have begun to level off recently. The remarkably 
stable smoking trends suggest that cessation rates are no 
longer increasing. The prevalence of cigarette smoking 
in Britain is indeed in danger of increasing again over 
the next few years [34], simply because more children 
and young people are starting to smoke. Almost a quar-
ter of Britain's 15-year-olds (21% of boys and 26% of 
girls) are regular smokers [23], despite the fact that it is 
illegal to sell cigarettes to children under age 16.  
An adverse effect of smoking on life expectancy 
has been reported from many population surveys [35-
37]. Using a computer simulation model, Tsevat et al 
estimated that population life expectancy would in-
crease 0.8 year by smoking cessation in 35-year old 
men [38]. Substantial benefit from reduction in smok-
ing would be expected for cardiovascular disease, 
chronic obstructive pulmonary disease and lung cancer 
[38]. Recognising the major impact of smoking on 
CHD and cancer mortality, bigger reductions in smok-
ing prevalence should therefore be targeted.  
All modelling studies such ours have limitations. 
They are particularly dependent on the quality and ex-
tent of data available on CHD risk factor trends and 
treatment uptakes. However, smoking data from Gen-
eral Household Survey are good. Due to the many limi-
tations in the data, extensive sensitivity analyses were 
performed to take into account the possible uncertain-
ties in our estimates. These did not greatly alter the 
relative contribution of each risk factor decline or 
treatment category. 
Lag times between changes in risk factors and 
changes in disease differ among diseases. For many 
carcinogens, the delay between exposure to a carcino-
gen and overt disease may be 20-30 years whereas for 
cardiovascular disease lag times are much shorter [39]. 
For example on quitting smoking or reducing choles-
terol, most of the risk reduction occurs within about 5 
years [19,29]. Lag times may therefore not be very im-
portant when considering a 20-year time period as in 
this CHD mortality model. 
In this study, a regression coefficient of 0.51, es-
timated from MONICA studies, was used to quantify 
the relationship between population changes in smoking 
prevalence and the consequent change in population 
mortality rates from CHD. However, the influence of 
smoking on CHD mortality may be even greater. The 
results from prospective observational studies con-
ducted in populations with a decreasing smoking preva-
lence may be biased by the misclassification of study 
subjects during the follow-up as a result of smoking 
cessation. This results in an underestimation of the risk 
of CHD caused by smoking [40]. For instance, in a 
study from Finland, the association between baseline 
smoking status and CHD weakened markedly when the 
follow-up time was extended. The risk ratio of cumula-
tive CHD mortality associated with smoking was 6.96 
in the first 2-year follow-up and it decreased gradually 
to 2.06 at the 20-year follow-up [40].  
Using similar methodology, smoking accounted 
for 36% of CHD deaths prevented or postponed in 
Scotland between 1975-1994 [16] and 30% in New 
Zealand between 1982-1993 [17]. Our findings were 
broadly consistent with studies from the US [41] and 
Europe [42]. This emphasises the importance of a na-
tional strategy to further reduce smoking with compre-
hensive tobacco control programmes.  
Many countries started tobacco control pro-
grammes in the 1970s and have had considerable suc-
cess in reducing smoking rates. Norway, Finland and 
Iceland all introduced advertising bans back in the 
1970s, which were followed by substantial reductions 
in smoking rates or tobacco consumption [43,44]. In 
1998, the UK Government published The White Paper 
on Tobacco [15], which aimed to reduce smoking 
prevalence from 28% in year 2000 to 24% by 2010 in 
the UK [45]. Despite some levelling off, the UK target 
may be achieved simply on the basis of current trends. 
In the US, smoking prevalence among adults was 24% 
in 2000 and the corresponding target is to reduce it to 
12% by 2010 [46]. The US target appears difficult to 
achieve, whereas the UK target is not challenging 
enough.  
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Appendix 1.  Medical and surgical treatments included in the model: data sources for treatment uptake levels 
and relative risk reductions 
 
TREATMENTS Source  (year)  Treatment  Up-
take in 2000 
(average) 
Source (year)  Relative Risk 
Reduction 
Acute myocardial in-
farction 
     
Community cardio-
pulmonary resuscitation 
UKHAS-Norris, 1998[1]  46%  BRESUS-Tunstall-
Pedoe[2]  
10% 
Hospital cardio-
pulmonary resuscitation 
UKHAS-Norris, 1998[1]  99%  BRESUS-Tunstall-
Pedoe[2]  
30% or 15% 
average 
Thrombolysis alone or in 
combination 
UKHAS-Norris, 1998[1]  35%  Collins(1996)[3]  12% 
Aspirin   UKHAS-Norris, 1998[1]  79%  Antithrombotic Trial-
ists' Collaboration 
(2002)[4] 
15% 
Primary angioplasty   David Cunningham, 
Myocardial Infarction 
National Audit Project 
(MINAP) (2002)- per-
sonal communication 
4% Keeley  (2002)[5]  30% 
Beta blocker  UKHAS-Norris, 1998[1]  19%  Freemantle (1999)[6]  4% 
ACE inhibitor  UKHAS-Norris, 1998[1]  19%  Latini  (2000)[7]  7% 
Secondary Prevention 
in CHD Patients 
    
 
 
Aspirin   Ryan(2001)[8]  61%  Antithrombotic Trial-
ists' Collaboration 
(2002)[4] 
15% 
Beta blocker   EUROASPIRE 
II(2001)[9;9] 
37% Freemantle  (1999)[6]  23% 
ACE inhibitor  EUROASPIRE 
II(2001)[9;9] 
21% 
 
Flather (2000)[10]  23% 
Statin Ryan(2001)[8]  50%  Pignone  (2000)[11]  29% 
Warfarin EUROASPIRE 
II(2001)[9;9] 
4% Lau  (1992)[12]  15% 
Rehabilitation   EUROASPIRE 
II(2001)[9;9] 
30% Taylor  (2002)  27% 
Chronic Angina       
CABG surgery   Society of Cardiothoracic 
Surgeons of Great Britain 
and Ireland[13] 
100% Yusuf  (1994)[14]  39% 
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Angioplasty   British Cardiac Interven-
tion Society(2002)[15]  
100% Keeley  (2002)[5]  16% 
Aspirin   Ryan(2001)[8]  50%  Antithrombotic Trial-
ists' Collaboration 
(2002)[4] 
15% 
Statins Ryan(2001)[8]  10%  Pignone  (2000)[11]  29% 
Unstable Angina       
Aspirin alone   Fox (2002)[16], Col-
linson (2000)[17] 
30% Antithrombotic  Trial-
ists' Collaboration 
(2002)[4] 
15% 
Aspirin & Heparin  Fox (2002)[16], Col-
linson (2000)[17] 
60% Antithrombotic  Trial-
ists' Collaboration 
(2002)[4] 
15% 
Platelet glycopro-
teinIIB/IIIA inhibitors 
Fox (2002)[16], Col-
linson (2000)[17] 
50% Boersma(2002)[18]  9% 
Heart Failure in the 
hospital 
 (2002)  46%     
ACE inhibitor  Clealand (2002)[19]  58%  Flather (2000)[10]  26% 
Beta blocker  Clealand (2002)[19]  28%  Shibata (2001)[20]  37% 
Spironolactone  Clealand (2002)[19]  10%  Pitt (1999)[21]  30% 
Aspirin  Clealand (2002)[19]  50%  Antithrombotic Trial-
ists' Collaboration 
(2002)[4] 
15% 
Statins Clealand  (2002)[19]  32%  Pignone  (2000)[11]  29% 
Heart Failure in the 
community 
     
ACE inhibitor  Ellis (2001)[22]  68%  Flather (2000)[10]  26% 
Beta blocker  Cleland (2002)[19] 
 
17% 
 
Shibata (2001)[20]  37% 
Spironolactone  Cleland (2002)[19]  12%  Pitt (1999)[21]  41% 
Aspirin  Ellis (2001) [22]  38%  Antiplatelet Trialists' 
Collaboration (1994)[23]  
15% 
Statin Cleland  (2002)[19]  43%  Pignone[11] 29% 
Hypertension  Health Survey for Eng-
land 1998(2001)[24] 
59% Collins  (1990)[25]  11% 
       
Statins for primary 
prevention 
Packham (2000)[26]    3% 
 
Pignone[11] 29% 
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Appendix 2.  Methodological Issues: β coefficients and interactions between risk factors and treatments    
 
There are a range of different coefficients or relative risks (RR) describing the relationship between each separate 
risk factors and CHD mortality. These vary somewhat in magnitude (see tables below).  
 
Estimated β coefficients from multiple regression analyses for the relationship between changes in population 
mean risk factors and changes in coronary heart disease mortality (men under 65 only) 
  Estimated β Coefficients 
Study Smoking  Cholesterol  Blood  Pressure 
Our 'best' estimates  0.51 2.00 1.67 
MONICA,  2000[27]  0.73 1.31 0.53 
Vartiainen et al. 1994[28]  0.70 2.00 1.67 
Sigfusson  1991[29]  0.51 2.22 1.06 
Dobson et al.  1996[30]  0.40 1.15 1.26 
Collins/MacMahon, 1990[25;31]  -  -  2.08 
Seven Countries[32;33]  -  2.10  2.09 
Law et al. 1994[34]  - 2.46 - 
Footnote: Vartiainen et al [28] and Sigfusson et al [29] are individual populations (Finland and Iceland respectively) 
from the MONICA study. Dobson et al 1996 [30] estimates are based on a subset of data from the MONICA study. 
Hence these estimates are not independent of each other. The major outcome in the MONICA 2000 [27] study was 
coronary event rate, as opposed to CHD mortality from the other MONICA studies.  
 
The MONICA coefficients could be considered 
the most appropriate, being the study to consider the 
impact of changes in risk factors on changes in CHD 
mortality at a population level. However, the MONICA 
coefficients have been repeatedly criticised for 'eco-
logical bias' and may underestimate the relationship 
between changes in risk factors and population trends in 
CHD mortality. This is because:  
1) Those who do not respond to risk factor sur-
veys may be at higher risk than attendees, and a de-
creasing response rate to MONICA surveys was ob-
served over the course of the study [27]. 
2) The major outcome from the MONICA study 
was all coronary events, not just CHD mortality, which 
may be expected to slightly dilute the β coefficients 
obtained.  
3) MONICA coefficients do not account for pos-
sible regression dilution bias; adjusted coefficients may 
be as much as 60% higher [34]. 
4) The principal MONICA estimates made no al-
lowance for a possible lag time between changes in the 
risk factor levels and changes in population CHD mor-
tality [27]. 
The MONICA coefficients for cholesterol and 
diastolic blood pressure are generally lower than from 
other sources [32,33], even constituent MONICA popu-
lations [28-30]. The MONICA coefficients have thus 
been used in our model as minimum estimates using the 
data for males only. In many cases, the number of 
events among females was too small to obtain reliable 
estimates, and the smoking coefficient appeared par-
ticularly anomalous. However, these global MONICA 
coefficients were mostly within the range of those esti-
mated from individual populations in the MONICA 
study, with the possible exception of blood pressure. 
Furthermore, these may be conservative, lacking 
the adjustment for regression dilution bias [35,36] 
recommended by some authors [34-36] but not all [37]. 
Coefficients derived from meta-analyses and the 
large cohort studies were regarded in our model as 
maximums. Maximum estimates were taken from Law 
et al for cholesterol [34], and Seven Countries for blood 
pressure [32,33], and best estimates were taken from 
the MONICA study in Iceland for blood pressure and 
smoking [29], and Finland for cholesterol [28]. The 
coefficients were reduced among older age groups to 
reflect good epidemiological evidence suggesting that 
relative risk is attenuated by age [34]. These 'maximum' 
coefficients may be overestimates being based on co-
hort analyses, which consider only the incremental ef-
fects of a risk factor on CHD mortality. These estimates 
are unlikely to be fully reversible when a population 
reduces its risk factor levels.  
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‘Best’ published values of relative risks for coronary heart disease mortality for obesity, diabetes, physical 
inactivity and deprivation.  
 Relative  Risk 
 Obesity 
(BMI>29kg/m
2) 
Diabetes Physical  activity  Deprivation 
Men  Stevens et al, 
1998[38], RRs 
ranged from 1.57 to 
2.33
# by age groups. 
Khaw et al, 
2001[39], 
RR=4.24*(1.92-
9.35)  
Shaper et al, British 
Regional Heart 
study, 1991[40] 
RR=0.50** (0.2-
0.8)  
Davey-Smith et al, 
Renfrew and Pais-
ley Study, 1998[41], 
RR=1.24(1.03-1.49) 
+ 
Women  Stevens et al, 
1998[38], RRs 
ranged from 1.00 to 
2.24
# by age groups. 
 Willett et 
al,1995[42]RR=3.5
6 (2.96-4.29) 
Female RRs x 1.5 
higher than male, 
(Members of the 
British Diabetic 
Association 
Study)[43]. 
Lee et al, Womens’ 
Health Study, 
2001[44], 
RR=0.55*** (0.37-
0.82) 
Davey-Smith et al, 
Renfrew and Pais-
ley Study, 1998[41], 
RR=1.44 (1.15-
1.80)
+ 
# Adjusted for age, education, physical activity, alcohol consumption. 
* Adjusted for age, serum cholesterol, systolic blood pressure, smoking, BMI, MI or stroke history.  
** Adjusted for BMI, social class, smoking, total cholesterol, HDL cholesterol, FEV1, breathlessness and heart rate.  
***Adjusted for age, treatment, smoking, alcohol, fat consumption, fibre, fruits and vegetables, use of hormones, 
postmenopausal status, parental history of MI at an early age.  
+ Adjusted for age, blood pressure, cholesterol, BMI, FEV1 score, smoking, angina, ECG ischeamia, and bronchitis. 
 
Independence Issues 
All these β coefficients and relative risks were obtained 
from multiple regression analyses; hence the interaction 
between the major risk factors should have been ac-
counted for. However, these estimates may still overes-
timate because most models, of necessity, entered data 
into the model on only a limited range of risk factors. 
For the MONICA study, these are smoking (yes or no), 
systolic blood pressure, total cholesterol, and body 
mass index [27]. There are many other important risk 
factors for CHD, including diet (such as consumption 
of fish oils and anti-oxidants), physical activity, afflu-
ence, employment and education. Some may be highly 
correlated with the four risk factors measured. It is 
likely, therefore, that the calculated coefficients contain 
the effects of some of these changes at a population 
level, as well as those in the measured risk factor.  
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